◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › IOVA

Iovance Biotherapeutics Inc (IOVA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-27

Iovance Biotherapeutics Inc (IOVA) operates in the BIOTECHNOLOGY industry and is headquartered in San Carlos, United States with about 975 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, IOVA reported $264M in revenue and ($391M) in net income.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Interactive charts & full statements → Open the IOVA valuation workbench →

IOVA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$324M	$264M	$164M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—
Gross Profit	$377M	$256M	$40M	($10M)	($21M)	($14M)	($9M)	($8M)	($1M)	($1M)	($1M)	($1M)	($9M)	($5M)	$0M	($19M)	—	—	—
Gross Margin %	116.4%	97.2%	24.4%	-804.5%	-8880.2%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($301M)	($403M)	($395M)	($461M)	($399M)	($343M)	($262M)	($207M)	($128M)	($93M)	($54M)	($28M)	($12M)	($23M)	($8M)	($21M)	($1M)	$0M	$0M
Operating Margin %	-92.9%	-153.1%	-240.9%	-38735.0%	-167595.8%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income	($289M)	($391M)	($372M)	($444M)	($390M)	($328M)	($260M)	($187M)	($124M)	($92M)	($53M)	($28M)	($12M)	($25M)	($3M)	($26M)	($2M)	$0M	$0M
Net Margin %	-89.2%	-148.4%	-226.8%	-37345.4%	-163833.2%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA	($263M)	($357M)	($331M)	($414M)	($378M)	($329M)	($261M)	($206M)	($127M)	($92M)	($53M)	($27M)	($12M)	($25M)	($8M)	($21M)	($2M)	$0M	$0M
Earnings Per Share (EPS)	$-0.73	$-1.09	$-1.28	$-1.89	$-2.45	$-2.14	$-1.88	$-1.50	$-1.27	$-1.41	$-0.96	$-0.62	$-0.48	$-2.60	$-4.14	$-33.84	$-2.46	$-0.02	$-0.05
Shares Outstanding (M)	450M	357M	290M	235M	159M	153M	138M	124M	97M	65M	55M	44M	25M	—	1M	1M	1M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IOVA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$99M	$71M	$87M	$67M	$60M	$49M	$74M	$59M
Gross Profit	$54M	$70M	$187M	$66M	$3M	$0M	$28M	$19M
Gross Margin %	54.6%	98.6%	215.9%	97.9%	5.5%	-0.9%	38.2%	32.0%
Operating Income (EBIT)	($52M)	($81M)	($73M)	($95M)	($114M)	($121M)	($87M)	($89M)
Operating Margin %	-52.3%	-113.5%	-84.7%	-140.7%	-189.8%	-245.8%	-117.5%	-152.1%
Net Income	($47M)	($79M)	($72M)	($91M)	($112M)	($116M)	($79M)	($84M)
Net Margin %	-47.6%	-110.7%	-82.9%	-135.3%	-186.2%	-235.5%	-106.6%	-142.7%
EBITDA	($39M)	($71M)	($68M)	($85M)	($98M)	($107M)	($65M)	($78M)
Earnings Per Share (EPS)	$-0.11	$-0.19	$-0.18	$-0.25	$-0.33	$-0.36	$-0.26	$-0.28
Shares Outstanding (M)	450M	419M	407M	364M	335M	323M	305M	303M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IOVA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Cash from Operations (CFO)	($265M)	($302M)	($353M)	($362M)	($293M)	($228M)	($205M)	($159M)	($101M)	($79M)	($33M)	($18M)	($9M)	($4M)	($2M)	($6M)	($1M)	$0M	$0M
Capital Expenditures (CapEx)	$32M	$34M	$11M	$22M	$20M	$38M	$47M	$7M	$1M	$1M	$2M	$1M	$2M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($297M)	($336M)	($364M)	($384M)	($313M)	($266M)	($252M)	($166M)	($102M)	($80M)	($34M)	($20M)	($10M)	($4M)	($2M)	($6M)	($1M)	$0M	$0M
FCF Margin %	-91.7%	-127.6%	-221.9%	-32305.3%	-131589.1%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dividends Paid	—	—	—	—	—	$1M	—	—	—	$0M	$49M	$0M	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IOVA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($61M)	($72M)	($53M)	($79M)	($67M)	($104M)	($73M)	($59M)
Capital Expenditures (CapEx)	$5M	$7M	$9M	$11M	$7M	$6M	$4M	$2M
Free Cash Flow (FCF)	($66M)	($79M)	($62M)	($90M)	($75M)	($110M)	($77M)	($61M)
FCF Margin %	-66.7%	-110.1%	-71.3%	-132.8%	-125.0%	-222.8%	-105.1%	-104.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IOVA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$916M	$913M	$910M	$780M	$664M	$777M	$768M	$345M	$481M	$155M	$172M	$106M	$47M	$20M	$0M	$1M	$1M	$0M	$0M
Cash & Cash Equivalents	$111M	$163M	$116M	$115M	$232M	$78M	$67M	$14M	$82M	$145M	$166M	$104M	$45M	$20M	$0M	$1M	$1M	$0M	$0M
Total Liabilities	$179M	$215M	$200M	$196M	$164M	$156M	$112M	$46M	$15M	$10M	$5M	$2M	$2M	$2M	$11M	$13M	$1M	$0M	$0M
Total Debt (Short + Long-Term)	$3M	$4M	$14M	$9M	$14M	$6M	$6M	$7M	$0M	$0M	$0M	$0M	$0M	$6M	$5M	$5M	$0M	$0M	$0M
Total Shareholders' Equity	$736M	$699M	$710M	$585M	$500M	$622M	$656M	$299M	$466M	$145M	$167M	$104M	$45M	$18M	($11M)	($13M)	$1M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IOVA viewer.

Other Companies in BIOTECHNOLOGY

ERAS · Erasca Inc — $5 billion
PBLS · Parabilis Medicines, Inc. Common Stock — $5 billion
EWTX · Edgewise Therapeutics Inc — $5 billion
ACAD · ACADIA Pharmaceuticals Inc — $5 billion
MANE · Veradermics, Incorporated — $4 billion
TLX · Telix Pharmaceuticals Limited — $4 billion
RLAY · Relay Therapeutics Inc — $4 billion
ABCL · Abcellera Biologics Inc — $4 billion

← IOTR All “I” companies IOYY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.